​The shareholders of LUXBRIGHT AB, reg. no. 556910-9837, (the "Company") are hereby invited to the annual general meeting on Thursday 25 June 2020, at 17.00 in the conference room on level 5 in the Company's premises at Arvid Wallgrens Backe 20 in Gothenburg, Sweden.

Aktieägarna i LUXBRIGHT AB, org. nr 556910-9837, ("Bolaget"), kallas härmed till årsstämma torsdagen den 25 juni 2020, kl. 17.00 i konferensrummet på plan 5 i Bolagets lokaler på Arvid Wallgrens Backe 20 i Göteborg.

EJ FÖR PUBLICERING, DISTRIBUTION, ELLER OFFENTLIGGÖRANDE HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I AUSTRALIEN, KANADA, HONG KONG, JAPAN, NYA ZEELAND, SINGAPORE, SYDAFRIKA, SCHWEIZ, USA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN HANDLING SKULLE VARA FÖRBJUDEN ENLIGT LAG ELLER KRÄVA REGISTRERING ELLER ANDRA ÅTGÄRDER.
​
Torsdagen den 30 april 2020 avslutades teckningsperioden i Luxbright AB:s (”Luxbright” eller ”Bolaget”) nyemission (”Erbjudandet”) för att kommersialisera produktförsäljningen och samtidigt förbereda Bolaget för en notering under hösten 2020. Erbjudandet om cirka 10,1 MSEK tecknades till cirka 12,5 MSEK, vilket motsvarar en teckningsgrad om cirka 123 procent. Styrelsen i Luxbright har därför beslutat att nyttja överteckningsoptionen och tilldela samtliga tecknare. Genom Erbjudandet tillförs Luxbright cirka 60 nya aktieägare.

The bigger the challenge, the bigger the opportunity. And the opportunities for Luxbright being created by the world’s “new normal” are more than ever before. We worked in our facility in China in January and were some of the last people to leave the country before the quarantines. Production started again in early March and we were some of the first ones to return to China. Now the country is preventing foreigners from entering. These are challenging times for us all, and yet in these challenges comes many opportunities. 

​Luxbright var på väg mot IPO i vintras. Den planerade kapitalinjektionen på runt 30 MSEK skulle skapa möjligheter att snabbt rampa upp produktionen i Kina och öka trycket på försäljning. Sen kom COVID-19. Följden har bl a varit att produktionen stått still i Kina under hela februari. Bolaget har använt tiden till att arbeta med produktionsförberedelser, se över komponenttillverkning, flyttat viss IP-känslig produktion till Sverige mm.  Fabriken öppnade sedan igen den 5 mars och den 11 mars var Luxbright tillbaka i Kina.  Produktionen av röntgenrör går nu för fullt. Luxbright har en back log på 1 MSEK och räknar med att sälja resten av produktionen i år till befintliga och potentiella kunder.

Nu genomförs en företrädesemission som vid fullteckning täcker bolagets finansiering till en notering. Kursen har mer än halverats jämfört med den tänkta IPO kursen i syfte att kraftigt gynna investerare som tecknar i nuvarande turbulens på aktiemarknaden.

Vi avser att göra en notering av vår aktie så fort marknaden tillåter det.

Det går bra att teckna utan företrädesrätt.

Teckningsperiod: 30 mars till 10 april

GOTHENBURG, SWEDEN–(16 March 2020) Luxbright AB, a leading creator of breakthrough X-ray technologies, is pleased to announce that IP Australia, the Australian Government agency that administers intellectual property (IP) rights, has granted the patent application for “An electron emitter for an x-ray tube.” The number of countries granting this patent continues to grow. Recently, China also granted this patent. 

GOTHENBURG, SWEDEN–(05 March 2020) Luxbright AB, a leading creator of breakthrough X-ray technologies, is pleased to announce that its patent application for “An electron emitter for an x-ray tube” has been approved by the China National Intellectual Property Administration (CNIPA). The granting of this patent is a valuable achievement and confirms the uniqueness of Luxbright’s cold cathode technology.

​The shareholders of LUXBRIGHT AB, reg. no. 556910-9837, (the "Company") are hereby invited to the extraordinary general meeting on Tuesday 24 March 2020, at 13:00 in the conference room on level 5 in the Company's premises at Arvid Wallgrens Backe 20 in Gothenburg, Sweden. Shareholders wishing to attend the extra general meeting must be recorded in the share register on the day of the general meeting and notify their and, if any, advisors participation to the Company by e-mail to [email protected] or by regular mail to the Company's address, no later than on 23 March 2020. 

Aktieägarna  i  Luxbright  AB,  556910-9837,  kallas  till  årsstämma  den  10  juni  2019  kl.  17.00  i konferensrummet på plan 5 vid bolagets lokaler på Arvid Wallgrens Backe 20 i Göteborg.

Shareholders of Luxbright AB, 556910-9837, are invited to attend the Annual General Meeting on June  10th,  2019  at  17:00  at  the Biotech  Center conference  room  on  level  5  located  at  the company's premises at Arvid Wallgrens Backe 20 in Gothenburg.

​GOTHENBURG, SWEDEN–(12 November 2018) Luxbright AB, a Swedish manufacturer of innovative microfocus X-ray tubes, is pleased to announce that its X-ray Device patent application has now been granted by the European Patent Office, Russian Federation, Mexico, and South Africa. The approvals mark a significant milestone for the company and validate the uniqueness of its X-ray innovation.

​Dating back to the 1700’s, the postal service in various countries has been used to transport packages intended to injure or even kill the recipient.

A more recent and infamous example is the USA terrorist “Unabomber,” also known as Ted Kaczynski, who killed and injured several people via mail bombs from 1978-1995. If you have not seen the Netflix Show “Manhunt Unabomber,” it may be time to do some binge-watching. Another example you may be more familiar with is the USA’s anthrax scare during 2001. A slew of anthrax-laced packages were sent that year killing five people and injuring seventeen. Preventative measures were quickly taken to help reduce the risk of further related incidents.

Nonetheless, postal threats remain a global issue. 

We hear a lot of buzz regarding how artificial intelligence (AI) will affect our future, but we don’t hear much in everyday conversation on how they will impact the X-ray space. AI technology is currently being used heavily in radiology to improve diagnosis.

A vast majority of the western world has had an X-ray taken at one point or another. X-rays help provide vital information to doctors on how to treat their patients. That said, X-rays use ionizing radiation which can increase the risk of cancer even in low doses.